Paz-Ares, L, Borghaei, H, Liu, S, Peters, S, Herbst, RS, Stencel, K, Majem, M, Sendur, MAN, Czyzewicz, G, Caro, RB, Lee, KH, Johnson, ML, Karadurmus, N, Grohé, C, Baka, S, Csoszi, T, Ahn, JS, Califano, R, Yang, TY, Kemal, Y, Ballinger, M, Cuchelkar, V, Graupner, V, Lin, YC, Chakrabarti, D, Bhatt, K, Cai, G, Iannone, R, Reck, M. Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trial. LANCET. 2025; 405(10495)DOI:10.1016/S0140-6736(25)01011-6. PMID:40473449. IF:88.500(Q1/1D).

Ochsenreither, S, Anguera, G, Dieter, S, Trikalinos, N, Fu, SQ, Fernández, BC, Ferrandiz, AC, Kim, SY, Rodriguez, LM, Berg, KCG, Hassan, HIB, Rosholm, A, Fredriksen, AB. Induction of neoantigen-specific immune responses by VB10.NEO in combination with atezolizumab in heavily pretreated patients with advanced solid tumors: Final analysis of the phase 1b VB N-02 trial.. JOURNAL OF CLINICAL ONCOLOGY. 2025; 43(16_SUPPL)DOI:10.1200/JCO.2025.43.16_suppl.2639. PMID:. IF:41.900(Q1/1D).

Herbst, RS, John, T, Grohé, C, Goldman, JW, Kato, T, Laktionov, K, Bonanno, L, Tiseo, M, Majem, M, Dómine, M, Ahn, MJ, Kowalski, DM, Pérol, M, Sriuranpong, V, Özgüroglu, M, Bhetariya, P, Markovets, A, Rukazenkov, Y, Muldoon, C, Robichaux, J, Hartmaier, R, Tsuboi, M, Wu, YL. Molecular residual disease analysis of adjuvant osimertinib in resected EGFR-mutated stage IB-IIIA non-small-cell lung cancer. NATURE MEDICINE. 2025; 31(6)DOI:10.1038/s41591-025-03577-y. PMID:40097663. IF:50.000(Q1/1D).

Tibau, A, Cliff, ERS, Romano, A, Borrell, M, Molto, C, Kesselheim, AS. Predictors of withdrawal of anticancer drug indications granted accelerated approval: a retrospective cohort study. Eclinicalmedicine. 2025; 84DOI:10.1016/j.eclinm.2025.103088. PMID:40687736. IF:10.000(Q1/1D).

Ortiz, MA, Anguera, G, Cantó, E, Alejandre, J, Mora, J, Osuna-Gómez, R, Mulet, M, Mora, P, Antonijuan, A, Sánchez, S, Ramírez, O, Orantes, V, Maroto, P, Vidal, S. Pilot Investigation on Markers of Bone Metabolism, Angiogenesis, and Neuroendocrine Activity as Potential Predictors of Survival of Metastatic Prostate Cancer Patients with Bone Metastases. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2025; 26(10)DOI:10.3390/ijms26104669. PMID:40429810. IF:4.900(Q1/3D).

Cappuzzo, F, Zvirbule, Z, Korbenfeld, E, Kolb-Sielecki, J, Isla, D, Szczesna, A, Sanchez, AYC, Bustillos, A, Liu, XY, Young, F, Tosti, N, Monteiro, MF, Majem, M. Primary Results from IMscin002: A Study to Evaluate Patient Preferences and Perceptions of Health Care Professionals for Atezolizumab Subcutaneous Versus Intravenous for the Treatment of NSCLC. Jto Clinical And Research Reports. 2025; 6(5)DOI:10.1016/j.jtocrr.2025.100815. PMID:40248457. IF:(Q/D).

Zuellig, JA, Adam, R, Udry, F, Tibau, A, Seruga, B, Ocana, A, Amir, E, Templeton, AJ. The Effect of Staging Intervals on Progression-Free Survival in Registration Studies of Oncologic Drugs: A Meta-Analysis. Cancers. 2025; 17(8)DOI:10.3390/cancers17081359. PMID:40282533. IF:4.400(Q2/3D).

Tibau, A, Romano, A, Kesselheim, AS. Will I feel better? Raising the bar for quality of life in oncology. Nature Reviews Clinical Oncology. 2025; 22(4)DOI:10.1038/s41571-025-01002-4. PMID:40021787. IF:82.200(Q1/1D).

Del Muro, XG, López-Bravo, DP, Cuéllar-Rivas, MA, Maroto, P, Giannatempo, P, Castellano, D, Climent, MA, Valderrama, BP, de Liaño, AG, López-Montero, L, Mina, L, Alcalá-López, D, Sampayo-Cordero, M, Necchi, A. Retifanlimab in Advanced Penile Squamous Cell Carcinoma: The Phase 2 ORPHEUS Study. European Urology Oncology. 2025; 8(2)DOI:10.1016/j.euo.2024.04.021. PMID:38749903. IF:9.300(Q1/1D).

Soo, RA, Vervita, K, Früh, M, Cho, B, Majem, M, Abreu, DR, Ribi, K, Callejo, A, Moran, T, Gomez, MD, Provencio, M, Addeo, A, Han, JY, Granados, ALO, Reck, M, Blasco, A, Campelo, RG, González, MAS, Britschgi, C, Roschitzki-Voser, H, Ruepp, B, Gasca-Ruchti, A, Haberecker, M, Dafni, U, Peters, S, Stahel, RA. A randomised non-comparative phase II study of atezolizumab, bevacizumab and chemotherapy in EGFR-mutant NSCLC with acquired resistance - The ETOP 15-19 ABC-lung trial. LUNG CANCER. 2025; 202DOI:10.1016/j.lungcan.2025.108454. PMID:40023017. IF:4.400(Q1/2D).

Borque-Fernando, A, Alonso-Gordoa, T, Juan-Fita, MJ, Campos, FL, Pérez-Fentes, DA, Vilaseca, A, Agut, CM, Usán, P, Rey, PM. Beyond the status quo: when disease volume and metastatic timing are not enough to personalize treatment in mHSPC. Future Oncology. 2025; 21(8)DOI:10.1080/14796694.2025.2468569. PMID:40029138. IF:2.600(Q3/6D).

Piedra, A, Guinart-Cuadra, A, Recio, SM, Mulet, M, Atenza, CZ, Alejandre, J, Beltran, JS, Joaquín, AB, Sullivan, IG, López, JS, Casado, MDI, Aperribay, EA, Paz-Ares, L, Tain, PD, Vega, ALM, Callejo, A, Martos, JLL, Dominguez, M, Vidal, S, Majem, M. Baseline PD-L1 expression in circulating neutrophils predicts immune-related adverse events (irAEs) in patients with extensive-stage small-cell lung cancer from CANTABRICO trial. Journal of Thoracic Oncology. 2025; 20(3)DOI:. PMID:. IF:20.800(Q1/1D).

Majem, M, O'Byrne, KJ, Lo Russo, G, Mueller, C, Triebel, F. TACTI-004: A double-blinded, randomized phase III trial in patients with advanced/metastatic non-small cell lung cancer receiving eftilagimod alfa (MHC class II agonist) in combination with pembrolizumab (P) and chemotherapy (C) versus placebo plus P plus C. Journal of Thoracic Oncology. 2025; 20(3)DOI:. PMID:. IF:20.800(Q1/1D).

Gillessen, S, Tombal, B, Turco, F, Choudhury, A, Rodriguez-Vida, A, Gallardo, E, Velho, PI, Nolè, F, Cruz, F, Loriot, Y, McDermott, R, Roumeguere, T, Daugaard, G, Yamamura, R, Bompas, E, Maroto, P, Polo, MH, da Trindade, KM, Preto, DD, Skoneczna, I, Lecouvet, F, Coens, C, Fournier, B, Saad, F. Decrease in Fracture Rate with Mandatory Bone-protecting Agents in the EORTC 1333/PEACE-3 Trial Comparing Radium-223 Combined with Enzalutamide Versus Enzalutamide Alone: A Safety Analysis. EUROPEAN UROLOGY. 2025; 87(3)DOI:10.1016/j.eururo.2024.11.027. PMID:39827019. IF:25.200(Q1/1D).

Casado, MDI, Aperribay, EA, Campelo, MRG, Blanco, MCM, Tain, PD, Piqueras, MMLB, Vega, ALM, Mateos, LAL, Rodriguez, JMO, Calderon, VG, Majem, M, Hernandez, AS, de la Rosa, CA, Cabellos, RA, Sureda, BM, Baret, M, Martos, JLL, Dominguez, M, Paz-Ares, L. Patient-reported outcomes from CANTABRICO: Durvalumab plus platinum-etoposide in first-line treatment of extensive stage small cell lung cancer. Journal of Thoracic Oncology. 2025; 20(3)DOI:. PMID:. IF:20.800(Q1/1D).

Majem, M, Gregorc, V, Lo Russo, G, Maio, M, Salvagni, S, Calderon, VG, Cao, MG, Contreras, SS, Koumarianou, A, Bearz, A, Caro, RB, Viteri, S, Sanmamed, MF, Zagouri, F, Bueno, MTM, Zhang, Y, Shan, Y, Zhu, H, Rosell, R. First-line (1L) fulzerasib plus cetuximab in KRAS G12Cm advanced NSCLC: Updated efficacy and safety from KROCUS study. Journal of Thoracic Oncology. 2025; 20(3)DOI:. PMID:. IF:20.800(Q1/1D).

Casado, MDI, Aperribay, EA, Campelo, MRG, Blanco, CM, Tain, PD, Piqueras, MMLB, Vega, ALM, Mateos, LAL, Rodriguez, JMO, Calderon, VG, Majem, M, Hernandez, AS, de la Rosa, CA, Cabellos, RA, Sureda, BM, Baret, M, Martos, JLL, Dominguez, M, Paz-Ares, L. Long-term survivors with extensive-stage small-cell lung cancer treated with first-line durvalumab plus carboplatin and etoposide: The CANTABRICO trial. Journal of Thoracic Oncology. 2025; 20(3)DOI:. PMID:. IF:20.800(Q1/1D).

Rueda-Lara, A, Viñal, D, Martínez-Pérez, D, Alameda-Guijarro, M, Martin-Montalvo, G, Martínez-Recio, S, Peña-Lopez, J, Jiménez-Bou, D, Ruíz-Gutiérrez, I, García-Leal, A, Zwisler-Contreras, P, Ghanem, I, Custodio, AB, Pérez-Wert, P, Gutiérrez-Sainz, L, Palacios, ME, Feliu, J, Rodríguez-Salas, N. Analysis of tumor budding as a prognostic factor for recurrence in patients with stage II and III colon cancer. Experience in a tertiary hospital. ONCOLOGIST. 2025; 30(3)DOI:10.1093/oncolo/oyaf027. PMID:40152315. IF:4.200(Q2/3D).

Fernandez-Mañas, L, Ortiz, I, Pozas, J, Beland, C, Larkin, J, Moll-Febrer, A, González-Aguado, L, Beltran, JS, Anguera, G, Navarro, N, Rodriguez-Vida, A, Novella, SR, Sierra, M, Carrasco, A, González, NS, Yonamine, EPM, Maeso, IG, Figols, M, Alcalá, MM, Reig, O. Impact of site of metastatic involvement on IMDC classification in metastatic renal cell carcinoma patients treated with immunotherapy.. JOURNAL OF CLINICAL ONCOLOGY. 2025; 43(5_SUPPL)DOI:10.1200/JCO.2025.43.5_suppl.483. PMID:. IF:41.900(Q1/1D).

Rioja, P, Passarella, C, Angel, M, Valderrama, W, Bosma, F, Anguera, G, Gomez, V, Ruiz-Granados, A, Plata, D, Laguado, MIZ, Orta-Ruiz, A, Gandur-Quiroga, MN, Bourlon, MT, Grande, E, Manneh, R, Molina-Cerrillo, J, Maroto-Rey, P, Sade, JP, Castellano, D. Impact of deferred cytoreductive nephrectomy in the era of the immunotherapy in metastatic renal cell carcinoma: A multicenter retrospective study.. JOURNAL OF CLINICAL ONCOLOGY. 2025; 43(5_SUPPL)DOI:10.1200/JCO.2025.43.5_suppl.502. PMID:. IF:41.900(Q1/1D).

Lista, AGD, Romero-Laorden, N, Gajate, P, Orta-Ruiz, A, Jiménez, JGD, Miranda, MJ, Estévez, SV, Molins, C, Pernaut, C, Cordero, MG, Fernández, O, Sánchez, JG, Maeso, IG, Blazquez, PR, Reig, O, Maroto-Rey, P, Martín, A, Ramirez, I, Puente, J. Effectiveness and safety of first-line atezolizumab in locally advanced or metastatic urothelial cancer: The IMFLAME study.. JOURNAL OF CLINICAL ONCOLOGY. 2025; 43(5_SUPPL)DOI:10.1200/JCO.2025.43.5_suppl.720. PMID:. IF:41.900(Q1/1D).

Cortellini, A, Brunetti, L, Di Fazio, GR, Garbo, E, Pinato, DJ, Naidoo, J, Katz, A, Loza, M, Neal, JW, Genova, C, Gettinger, S, Kim, SY, Jayakrishnan, R, El Zarif, T, Russano, M, Pecci, F, Di Federico, A, Awad, M, Alessi, J, Montrone, M, Owen, DH, Signorelli, D, Fidler, MJ, Li, MJ, Camerini, A, De Giglio, A, Young, L, Vincenzi, B, Metro, G, Passiglia, F, Yendamuri, S, Guida, A, Ghidini, M, Awosika, NO, Napolitano, A, Fulgenzi, CAM, Grisanti, S, Grossi, F, D'Incecco, A, Josephides, E, Van Hemelrijck, M, Russo, A, Gelibter, A, Spinelli, G, Verrico, M, Tomasik, B, Giusti, R, Newsom-Davis, T, Bria, E, Sebastian, M, Rost, M, Forster, M, Mukherjee, U, Landi, L, Mazzoni, F, Aujayeb, A, Dupont, M, Curioni-Fontecedro, A, Chiari, R, Pantano, F, Morabito, A, Leonetti, A, Friedlaender, A, Addeo, A, Zoratto, F, De Tursi, M, Cantini, L, Roca, E, Mountzios, G, Della Gravara, L, Kalvapudi, S, Inno, A, Bironzo, P, Barros, RD, O'Reilly, D, Bell, J, Karapanagiotou, E, Monnet, I, Baena, J, Macerelli, M, Majem, M, Agustoni, F, Cortinovis, DL, Tonini, G, Minuti, G, Bennati, C, Mezquita, L, Gorría, T, Servetto, A, Beninato, T, Lo Russo, G, Rogado, J, Moliner, L, Biello, F, Nana, FA, Dingemans, AM, Aerts, JGJ, Ferrara, R, Torri, V, Abu Hejleh, T, Takada, K, Naqash, AR, Garassino, M, Peters, S, Wakelee, H, Nassar, AH, Ricciuti, B. Determinants of 5-year survival in patients with advanced NSCLC with PD-L1=50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry. Journal for ImmunoTherapy of Cancer. 2025; 13(2)DOI:10.1136/jitc-2024-010674. PMID:39904562. IF:10.600(Q1/1D).

Castro, CG, López, S, Garcia-Alfonso, P, Martinez, CF, González, BD, Ortiz, MJ, Paez, D, Lopez, CM, La Casta, A, Sosa, MM, Valera, JS, Ghanem, I, Vidal-Tocino, R, Santos, C, Garcia-Benito, C, Jimenez, E, Guillot, M, Verdaguer, H, Montes, AFF. A cross-sectional analysis from a real-world cohort of patients with microsatellite instability colorectal cancer (MSI-CRC) with metastatic disease from the Spanish RETUD registry.. JOURNAL OF CLINICAL ONCOLOGY. 2025; 43(4_SUPPL)DOI:10.1200/JCO.2025.43.4_suppl.178. PMID:. IF:41.900(Q1/1D).

Martelli, V, Barrull, JV, Fernandez-Rodríguez, C, Gibert, J, Moreno, A, Louhamane, A, Linares-Aceituno, J, Garcia-Alfonso, P, Paez, D, Alonso, V, Espana, MAG, Santos, C, Duran, G, Elez, E, Paricio, BB, Tabernero, J, Salazar, R, Aranda, E, Toledo, RA, Montagut, CO. Plasma shallow whole-genome sequencing profiling in patients with RASWT metastatic colorectal cancer (mCRC) undergoing first-line anti-EGFR therapy.. JOURNAL OF CLINICAL ONCOLOGY. 2025; 43(4_SUPPL)DOI:10.1200/JCO.2025.43.4_suppl.214. PMID:. IF:41.900(Q1/1D).

Montes, AFF, Lopez, CM, Lopez, S, Martinez, CF, Paez, D, Gonzalez, BD, Espana, MAG, Garcia-Benito, C, Vidal-Tocino, R, Sosa, MM, Valera, JS, Garcia-Alfonso, P, Ghanem, I, La Casta, A, Gallego, J, Verdaguer, H, Santos, C, Jimenez, E, Gravalos, C. A cross-sectional analysis from a real-world cohort of patients with microsatellite instability colorectal cancer (MSI-CRC) with localized disease from the Spanish RETUD registry.. JOURNAL OF CLINICAL ONCOLOGY. 2025; 43(4_SUPPL)DOI:10.1200/JCO.2025.43.4_suppl.173. PMID:. IF:41.900(Q1/1D).

Olmos, VP, Pollán, M, de Larrea-Baz, NF, Fernández-Morata, J, Ruiz-Moreno, E, García-Pérez, J, Castelló, A, Sierra, MA, Lucas, P, Alonso-Ledesma, I, Stradella, A, Cantos, B, Cajal, TRY, Santisteban, M, Seguí, MA, Bertrán, AS, Granja, M, Camps-Herrero, J, Recalde, S, Mendez, M, Verges, NC, Pérez-Gómez, B, Pastor-Barriuso, R, Lope, V. Determinants of Adherence to World Cancer Research Fund/American Institute for Cancer Research Recommendations in Women with Breast Cancer. Cancers. 2025; 17(4)DOI:10.3390/cancers17040708. PMID:40002301. IF:4.400(Q2/3D).

Flix-Valle, A, Medina, JC, Souto-Sampera, A, Arizu-Onassis, A, Juan-Linares, E, Serra-Blasco, M, Ciria-Suárez, L, Feixas, G, Ochoa-Arnedo, C. Therapeutic alliance in a stepped digital psychosocial intervention for breast cancer patients: findings from a multicentre randomised controlled trial. BJPsych Open. 2025; 11(1)DOI:10.1192/bjo.2024.844. PMID:39865983. IF:3.500(Q1/3D).

Martin-Broto, J, Diaz-Beveridge, R, Moura, D, Ramos, R, Martinez-Trufero, J, Carrasco, I, Sebio, A, Gonzalez-Billalabeitia, E, Gutierrez, A, Fernandez-Jara, J, Hernandez-Vargas, L, Cruz, J, Valverde, C, Hindi, N. Phase Ib Study for the Combination of Doxorubicin, Dacarbazine, and Nivolumab as the Upfront Treatment in Patients With Advanced Leiomyosarcoma: A Study by the Spanish Sarcoma Group (GEIS). JOURNAL OF CLINICAL ONCOLOGY. 2025; 43(3)DOI:10.1200/JCO.24.00358. PMID:39356980. IF:41.900(Q1/1D).

Martinez-Recio, S, Molina-Pérez, MA, Muñoz-Couselo, E, Sevillano-Tripero, AR, Aya, F, Arance, A, Orrillo, M, Martin-Liberal, J, Fernandez-Morales, L, Lesta, R, Quindós-Varela, M, Nieva, M, Vidal, J, Martinez-Perez, D, Barba, A, Majem, M. Adjuvant Immunotherapy After Resected Melanoma: Survival Outcomes, Prognostic Factors and Patterns of Relapse. Cancers. 2025; 17(1)DOI:10.3390/cancers17010143. PMID:39796770. IF:4.400(Q2/3D).

Sebio, A, Berger, C, Tabone, MD, Fernandez, N, Tardy, F, Grootenhuis, M, Palmerini, E, Gaspar, N, van de Sande, M, Haveman, LM. Quality of Life and Patient-Reported Outcomes in Patients With Osteosarcoma: A Systematic Review. EUROPEAN JOURNAL OF CANCER CARE. 2025; 2025(1)DOI:10.1155/ecc/5802523. PMID:. IF:1.900(Q2/4D).

Piedra, A, Martínez-Recio, S, Hernández, A, Morán, T, Arriola, E, Recuero-Borau, J, Cobo, M, Cordeiro, P, Mosquera, J, Fernández, M, García-Campelo, R, Calles, A, Alvarez, R, Zapata-García, M, Isla, D, Callejo, A, Iranzo, P, Serra-López, J, Barba, A, Sullivan, I, Felip, E, Majem, M. First-line pembrolizumab in patients with advanced non-small cell lung cancer and high PD-L1 expression: real-world data from a Spanish multicenter study. Frontiers in Oncology. 2024; 14DOI:10.3389/fonc.2024.1510278. PMID:39741981. IF:3.300(Q2/4D).

Soria Rivas A, Escobar Álvarez Y, Blasco Cordellat A, Majem Tarruella M, Molina Mata K, Motilla de la Cámara M, Del Mar Muñoz Sánchez M, Zafra Poves M, Beato Zambrano C, Cabezón Gutierrez L. SEOM clinical guidelines for cancer anorexia-cachexia syndrome (2023).. Clinical & Translational Oncology. 2024; 26(11)DOI:10.1007/s12094-024-03502-8. PMID:38822976. IF:(Q/D).

Volta-Duran, E, Sanchez, JM, Hector-Lopez-Laguna, Parlade, E, Sanchez-Garcia, L, Sanchez-Chardi, A, de Marco, A, Unzueta, U, Vazquez, E, Villaverde, A. The spectrum of building block conformers sustains the biophysical properties of clinically-oriented self-assembling protein nanoparticles. Science China-Materials. 2022; 65(6)DOI:10.1007/s40843-021-1914-0. PMID:. IF:8.100(Q1/3D).

Parlade, E, Volta-Duran, E, Cano-Garrido, O, Sanchez, JM, Unzueta, U, Lopez-Laguna, H, Serna, N, Cano, M, Rodriguez-Mariscal, M, Vazquez, E, Villaverde, A. An In Silico Methodology That Facilitates Decision Making in the Engineering of Nanoscale Protein Materials. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2022; 23(9)DOI:10.3390/ijms23094958. PMID:35563346. IF:5.600(Q1/3D).

Barguilla, I, Unzueta, U, Carratala, JV, Cano-Garrido, O, Villaverde, A, Hernandez, A, Ferrer-Miralles, N. Toxicity Profiling of Bacterial Inclusion Bodies in Human Caco-2 Cells. Frontiers in Bioengineering and Biotechnology. 2022; 10DOI:10.3389/fbioe.2022.842256. PMID:35573225. IF:5.700(Q1/3D).

Sanchez, JM, Carratala, JV, Serna, N, Unzueta, U, Nolan, V, Sanchez-Chardi, A, Volta-Duran, E, Lopez-Laguna, H, Ferrer-Miralles, N, Villaverde, A, Vazquez, E. The Poly-Histidine Tag H6 Mediates Structural and Functional Properties of Disintegrating, Protein-Releasing Inclusion Bodies. Pharmaceutics. 2022; 14(3)DOI:10.3390/pharmaceutics14030602. PMID:35335976. IF:5.400(Q1/2D).

López-Laguna H, Voltà-Durán E, Parladé E, Villaverde A, Vázquez E, Unzueta U. Insights on the emerging biotechnology of histidine-rich peptides. BIOTECHNOLOGY ADVANCES. 2022; 54DOI:10.1016/j.biotechadv.2021.107817. PMID:34418503. IF:16.000(Q1/1D).

Serna, N, Carratala, JV, Conchillo-Sole, O, Martinez-Torro, C, Unzueta, U, Mangues, R, Ferrer-Miralles, N, Daura, X, Vazquez, E, Villaverde, A. Antibacterial Activity of T22, a Specific Peptidic Ligand of the Tumoral Marker CXCR4. Pharmaceutics. 2021; 13(11)DOI:10.3390/pharmaceutics13111922. PMID:34834337. IF:6.525(Q1/2D).

Lopez-Laguna, H, Sanchez, JM, Carratala, JV, Rojas-Pena, M, Sanchez-Garcia, L, Parlade, E, Sanchez-Chardi, A, Volta-Duran, E, Serna, N, Cano-Garrido, O, Flores, S, Ferrer-Miralles, N, Nolan, V, de Marco, A, Roher, N, Unzueta, U, Vazquez, E, Villaverde, A. Biofabrication of functional protein nanoparticles through simple His-tag engineering. ACS Sustainable Chemistry & Engineering. 2021; 9(36)DOI:10.1021/acssuschemeng.1c04256. PMID:34603855. IF:9.224(Q1/1D).

Sanchez-Garcia, L, Volta-Duran, E, Parlade, E, Mazzega, E, Sanchez-Chardi, A, Serna, N, Lopez-Laguna, H, Mitstorfer, M, Unzueta, U, Vazquez, E, Villaverde, A, de Marco, A. Self-Assembled Nanobodies as Selectively Targeted, Nanostructured, and Multivalent Materials. ACS Applied Materials & Interfaces. 2021; 13(25)DOI:10.1021/acsami.1c08092. PMID:34129336. IF:10.383(Q1/2D).